In which clinical situations is there a good rationale for the use of proton therapy for GI cancers?

The biology of smaller fraction size is dominant with re-RT. Unless everything in the high dose volume (includes margin) can take that dose with low risk, smaller fraction sizes are preferred. IMRT allows more control of where the dose goes and better sparing of nearby sensitive organs than protons ...